Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001410578-25-000285
Filing Date
2025-03-06
Accepted
2025-03-06 16:24:53
Documents
93
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tmb-20241231x10k.htm   iXBRL 10-K 2702279
2 EX-10.36 tmb-20241231xex10d36.htm EX-10.36 109881
3 EX-19.1 tmb-20241231xex19d1.htm EX-19.1 56532
4 EX-21.1 tmb-20241231xex21d1.htm EX-21.1 14317
5 EX-23.1 tmb-20241231xex23d1.htm EX-23.1 6322
6 EX-31 tmb-20241231xex31.htm EX-31 14572
7 EX-32 tmb-20241231xex32.htm EX-32 7484
8 GRAPHIC tmb-20241231x10k001.jpg GRAPHIC 51376
9 GRAPHIC tmb-20241231x10k002.jpg GRAPHIC 54975
  Complete submission text file 0001410578-25-000285.txt   11461827

Data Files

Seq Description Document Type Size
10 EX-101.SCH tmb-20241231.xsd EX-101.SCH 76248
11 EX-101.CAL tmb-20241231_cal.xml EX-101.CAL 80502
12 EX-101.DEF tmb-20241231_def.xml EX-101.DEF 296786
13 EX-101.LAB tmb-20241231_lab.xml EX-101.LAB 647690
14 EX-101.PRE tmb-20241231_pre.xml EX-101.PRE 486804
96 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20241231x10k_htm.xml XML 1850133
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-12584 | Film No.: 25715632
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)